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Abstract 
Myotonic dystrophy is a multisystemic disorder characterized by repeat expansion 
mutations of the dystrophia myotonica protein kinase (DMPK) gene resulting in a 
defective muscular insulin receptor and insulin resistance. We describe a patient with 
myotonic dystrophy who developed biopsy-proven non-alcoholic steatohepatitis. We 
suggest that patients with myotonic dystrophy are at risk of developing steatohepatitis. 
The relationship between defective insulin receptor and development of steatohepatitis 
should be further investigated. 
 
Introduction 
Myotonic dystrophy in a complex multisystemic autosomal dominant disorder 
characterized by two different mutations resulting in an unstable CTG repeat expansion 
in the 3c untranslated region of the dystrophia myotonica protein kinase (DMPK) gene on 
chromosome 19 (myotonic dystrophy type 1) and a CCTG repeat expansion in intron 1 
on zinc finger protein 9 on chromosome 3 (myotonic dystrophy type 2) [1, 2]. It is the 
most common form of muscular dystrophy with an incidence of 1:8,000 worldwide [3]. 
Symptoms are multisystemic and include muscle hyperexcitability, progressive muscle 
weakness, cataract development, testicular atrophy and cardiac arrhythmias [4]. Insulin 
resistance in myotonic dystrophy correlates with a failure to express the insulin receptor 
splice variant that normally predominates in adult skeletal muscle, leading to the  
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expression of an insulin receptor variant with a lower signaling capability. Muscles of 
myotonic dystrophy 1 patients contain lower than normal levels of insulin receptor RNA 
and protein. This results in reduced responsiveness of muscle to insulin compared to 
normal individuals [5, 6], confirming previous studies which suggested that metabolic 
abnormalities which may lead to glucose intolerance were related to insulin response 
defects [7]. Hepatic dysfunction in patients with myotonic dystrophy is common and 
includes chronic liver disease and gallbladder dismotility [8]. One study showed that an 
approximate 66% of patients with myotonic dystrophy 1 had at least one abnormality of 
liver enzymes [9]. 
In this article we describe the case of a patient with myotonic dystrophy and 
non-alcoholic steatohepatitis (NASH) and discuss the possible links between the 
myotonic dystrophy genetic defect and development of steatohepatitis. 
Case Report 
The patient was a 39-year-old male with a history of myotonic dystrophy who was being evaluated 
for abnormal liver function tests. He denied alcohol or tobacco use. Family history was negative for liver 
disease. He had a medical history of hypertension that was well controlled on Diovan. His BMI was 38.  
At physical examination the liver margin was felt at deep inspiration and was smooth. The spleen 
was not enlarged and there was no ascites. He had no stigmata of chronic liver disease. Abnormal 
laboratory values included total bilirubin 2.5 mg/dl (normal 0.2–1.2), indirect bilirubin 2.1 mg/dl, AST 
71 U/l (normal 10–40), ALT 96 U/l (normal 9–60), gamma-GT 126 U/l (normal 3–90). Viral hepatitis 
serologies and autoimmune panel were negative. Glycemic control was normal. MRI of the abdomen 
showed moderate fatty infiltration of the liver. The gallbladder and biliary tree were unremarkable. A 
liver biopsy was performed which showed a moderate degree of macrovescicular steatosis with foci of 
hepatocellular inflammation suggestive of steatohepatitis. There was pericentral and perisinusoidal 
fibrosis with occasional septal extension (fig. 1). 
Discussion 
We suggest that patients with myotonic dystrophy are at increased risk of developing 
hepatocytic inflammation/NASH through the same pathways that are seen in patients 
with metabolic syndrome, i.e. abnormalities in insulin receptor and glucose intolerance 
leading to elevated free fatty acid oxidation and reactive oxygen species. These abnormal 
metabolic pathways promote hepatocyte inflammation which in turn can increase the risk 
of development of hepatic cirrhosis and carcinoma. NASH, a common cause of 
cryptogenic cirrhosis and hepatocellular carcinoma, is characterized by fatty infiltration 
of the liver, inflammation, hepatocellular damage and fibrosis. It is seen in a subset of 
patients with non-alcoholic fatty liver disease (NAFLD) which is a well-known hepatic 
manifestation seen in patients with the metabolic syndrome (which includes insulin 
resistance, hypertriglyceridemia, hypertension and obesity) [10]. 
The etiology of elevated liver tests in patients with myotonic dystrophy has been 
suggested to arise from two possible mechanisms: (1) elevated AST from skeletal muscle 
breakdown as correlated with creatine kinase elevations and (2) biliary contraction/bile 
excretion abnormalities. These laboratory abnormalities in patients with myotonic 
dystrophy type 1 include changes in serum creatine kinase, AST/ALT and fasting blood 
glucose [11]. Increase in ALT, alkaline phosphatase and gamma-GT activity has been 
reported to be specific of liver involvement in patients with myotonic dystrophy [12]. 
However the link between myotonic dystrophy and liver disease remains controversial. 
Biochemical abnormalities seen in myotonic dystrophy patients have been described to be  
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mainly secondary to muscular damage and falsely attributed to the liver, leading to costly 
and unnecessary liver investigations [13, 14]. Some have suggested alterations in the 
contractility of bile canaliculi and bile ductules that may lead to incomplete biliary 
obstruction and impaired bile excretion as an etiology [9]. 
A recent study showed decreased insulin receptor RNA and protein not only in skeletal 
muscle but also in the liver (up to an 80% decrease) [15]. We suggest that the resulting 
insulin resistance in hepatocytes and other tissues leads to hepatocyte damage similar to 
that seen in NASH. The mechanism of damage in NASH/NAFLD has been related to 
insulin resistance even in the absence of obesity or diabetes. Insulin resistance leads to an 
increase in circulating free fatty acids because of the decreased antilipolytic effects of 
insulin in adipose tissue. Also, mitochondrial dysfunction secondary to insulin resistance 
leads to increased formation of reactive oxygen species in hepatocytes leading to 
inflammation. In vitro studies have identified a CUG-binding protein that binds to the 
anomalous triplet expansions in myotonic dystrophy 1 [16, 17]. CUG-binding protein 
activity is increased as a result of this interaction in myotonic dystrophy 1 which leads to 
aberrant splicing defects in chloride channel 1 and insulin receptor RNA resulting in 
myotonia and insulin receptor defects [5, 18, 19]. 
 
 
 
 
 
Fig. 1. Core needle biopsy of the liver. Findings include a moderate degree of macrovesicular steatosis 
with foci of hepatocellular inflammation. Trichrome stain demonstrates increased sinusoidal and 
pericentral fibrosis with occasional septal fibrosis. 
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